(13223324), S. R. M., (22676321), A. R., (22676324), M. A. P., (22676327), E. Z. E., (22676330), M. D., (3480455), H. H., . . . (22676354), M. J. Y. A. (2025). The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
Chicago Style (17th ed.) Citation(13223324), Seyed Reza Mousavi, et al. The Non-inferiority Margin in Phase III Clinical Trial of SnaFab Compared to Razi Antivenom in Snakebites. 2025.
MLA (9th ed.) Citation(13223324), Seyed Reza Mousavi, et al. The Non-inferiority Margin in Phase III Clinical Trial of SnaFab Compared to Razi Antivenom in Snakebites. 2025.
Warning: These citations may not always be 100% accurate.